8-K: Regen Biopharma Restates Prior Financial Statements Due to Accounting Errors

Regen Biopharma's Board of Directors determined that previously issued financial statements for the year ended September 30, 2024, should not be relied upon due to required revisions.

Summary

• Regen Biopharma has restated its previously issued unaudited financial statements for the year ended September 30, 2024.
• The restatement was deemed necessary by the Board of Directors on May 13, 2025, due to errors in the initial filings.
• Key adjustments include a revision to the value of common shares issued as non-employee compensation, corrected market price for calculating Derivative Liability, and reclassification of Unrealized Losses on Investment Securities.
• The value of 249,915 common shares issued as nonemployee compensation has been adjusted to $0.1499 per share.
• The market price utilized in calculating Derivative Liability as of September 30, 2024 has been corrected to $0.1027 per share.
• $204,847 in Unrealized Losses on Investment Securities has been reclassified as Other Comprehensive Income.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the restatement of financial statements, indicating prior accounting errors and potential weaknesses in internal controls. This can erode investor confidence.

Negatives

• The need to restate financial statements indicates prior accounting errors.
• The restatement impacts key financial metrics, potentially affecting investor confidence.
• The company had to adjust the value of common shares issued as non-employee compensation to $0.1499 per share.
• The market price utilized in calculating Derivative Liability as of September 30, 2024 has been corrected to $0.1027 per share.
• The company had to reclassify $204,847 in Unrealized Losses on Investment Securities as Other Comprehensive Income.

Risks

• Restating financial statements can lead to increased scrutiny from regulators and investors.
• The identified accounting errors may indicate weaknesses in internal controls.
• The restatement could negatively impact the company's reputation and stock price.

Management Comments

• The Company's senior management has discussed the matters disclosed in this Item 4.02 of this Current Report with BCRG Group, the Company's independent registered public accounting firm.

Industry Context

Financial restatements are not uncommon, particularly among smaller companies. However, they can raise concerns about the reliability of financial reporting and internal controls. Investors often compare the nature and magnitude of restatements to those of peer companies to assess the severity of the issue.

Comparison to Industry Standards

• It's difficult to directly compare this restatement to industry standards without knowing the specific reasons for the errors and the company's size and complexity.
• However, similar biotech companies like Lineage Cell Therapeutics or BioTime (now AgeX Therapeutics) have faced scrutiny over accounting practices in the past.
• The materiality of the restatement, as a percentage of key financial metrics, would be a key factor in assessing its significance compared to industry benchmarks.

Related Party Transactions

• Accounts Receivable, Related Party is listed as $94,873.
• Investment Securities, Related Party is listed as $17,733.
• Revenues, Related Party is listed as $110,000.

Stakeholder Impact

• Shareholders may experience a decline in stock value due to the restatement.
• Employees may face uncertainty due to potential internal control reviews.
• Creditors may reassess the company's creditworthiness.

Key Dates

Keywords

financial restatement, accounting errors, financial statements, Regen Biopharma, derivative liability, common shares, unrealized losses